CINPHA: Phase 3 trial for linaprazan glurate advances, with robust cash reserves and ongoing global expansion

Phase 3 for linaprazan glurate in severe erosive GERD is underway, with patient recruitment on track and topline results expected in H2 2026. Q3 2025 saw higher R&D expenses and a net loss, but a strong cash position remains, supported by licensing deals.

Original document: Cinclus Pharma Holding AB [CINPHA] Slides Release — Nov. 20 2025